Key features and details
- Rabbit polyclonal to Fibrinogen
- Suitable for: WB, ELISA, IHC-P
- Reacts with: Mouse
- Isotype: IgG
Product nameAnti-Fibrinogen antibody
See all Fibrinogen primary antibodies
DescriptionRabbit polyclonal to Fibrinogen
SpecificityAb27913 recognises fibrinogen.
Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
Species reactivityReacts with: Mouse
Full length native protein (purified): Mouse fibrinogen isolated from plasma using several chromatographic steps.
- This antibody gave a positive result in IHC in the following FFPE tissue: Mouse Liver.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Avoid freeze / thaw cycle.
Storage bufferConstituent: Whole serum
Concentration information loading...
Our Abpromise guarantee covers the use of ab27913 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000. Predicted molecular weight: 95 kDa.|
|IHC-P||Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracellular medium.
- Information by UniProt
- FGA antibody
- FGB antibody
- FGG antibody
IHC image of Fibrinogen staining in Mouse Liver formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab27913, 1 µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ab27913 has been referenced in 5 publications.
- Uyama N et al. Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation. Sci Rep 9:17558 (2019). PubMed: 31772282
- Masuda H et al. Batroxobin accelerated tissue repair via neutrophil extracellular trap regulation and defibrinogenation in a murine ischemic hindlimb model. PLoS One 14:e0220898 (2019). PubMed: 31419236
- Wan H et al. Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage. J Thromb Haemost 16:1413-1422 (2018). PubMed: 29729651
- Zhang Y et al. Inverse agonist of ERR? reduces cannabinoid receptor type 1-mediated induction of fibrinogen synthesis in mice with a high-fat diet-intoxicated liver. Arch Toxicol 92:2885-2896 (2018). PubMed: 30019168
- Nordstrom SM et al. Increased thrombosis susceptibility and altered fibrin formation in STAT5-deficient mice. Blood 116:5724-33 (2010). WB ; Mouse . PubMed: 20823455